Patent 10,166,286: Claims and Landscape Analysis
What does United States Patent 10,166,286 cover?
Patent 10,166,286, issued to Bristol-Myers Squibb on October 30, 2018, relates to a monoclonal antibody targeting PD-1 (programmed death-1 receptor) with modifications that enhance its therapeutic properties. The patent claims include specific antibody sequences, methods of use, and pharmaceutical compositions for treating diseases such as cancers, including melanoma, non-small cell lung cancer, and other solid tumors.
Key Claims Breakdown:
- Antibody Sequences: The patent protects certain amino acid sequences of anti-PD-1 antibodies, emphasizing variable regions and complementarity-determining regions (CDRs).
- Modified Antibodies: Claims encompass antibodies with amino acid modifications that improve binding affinity, reduce immunogenicity, or alter Fc effector functions.
- Methods of Use: Therapeutic applications, specifically clinical methods involving administering the antibody to treat PD-1 associated diseases.
- Pharmaceutical Compositions: Formulations, dosing regimens, and combinations with other therapeutic agents.
How broad and enforceable are the claims?
Scope: The patent’s claims are moderately broad, covering specific antibody sequences and their variants with certain modifications. Claims include both the antibodies themselves and their methods of therapeutic application.
Enforceability Concerns: Several claims are limited to particular amino acid sequences, reducing risk of overbroad invalidation but also constraining coverage. The claim language emphasizes "isolated" antibodies with specified CDRs, a common approach in antibody patents to balance scope and descriptiveness.
Priority and Continuity: The patent is a continuation of earlier applications, notably US Patent 9,055,646. This lineage consolidates prior art and may bolster enforcement; however, prior art references, including earlier anti-PD-1 patents and antibodies (e.g., pembrolizumab), present potential challenges.
What is the patent landscape for anti-PD-1 antibodies?
The anti-PD-1 space features several key patents and patent applications:
| Patent/Application |
Holder |
Focus |
Issue/Publication Date |
Notable Claims |
| US 9,055,646 |
Bristol-Myers Squibb |
Original anti-PD-1 antibodies |
June 7, 2015 |
Base sequences, therapeutic methods |
| WO 2017/043055 |
Merck |
Antibodies with modified Fc regions, enhanced stability |
March 16, 2017 |
Fc engineering, antibody variants |
| US 8,888,279 |
Merck |
PD-1 binding molecules |
Nov 11, 2014 |
Alternative sequences, bispecifics |
| Pending applications |
Various |
Combination therapies, immune modulators |
Ongoing |
Device and method claims |
This landscape indicates a crowded patent space with overlapping claims, particularly around antibody sequences, Fc modifications, and combination therapeutic methods.
Competitor Summary:
- Merck & Pfizer: Hold patents covering modified Fc antibodies, bispecifics, and combination treatments with PD-1 inhibitors.
- Eli Lilly: Has filed applications relating to checkpoint inhibitors and their use with other immuno-oncology agents.
- Innovator Risks: Patent infringement may involve multiple overlapping patents, requiring comprehensive freedom-to-operate analyses.
How does US 10,166,286 compare to prior art?
The patent builds upon earlier anti-PD-1 patents by Bruhn et al. (e.g., US 9,055,646), with additional claims directed at antibody modifications. Its novelty lies in specific amino acid substitutions that aim to optimize therapeutic efficacy or reduce adverse effects.
Key differences include:
- Sequence Variants: The patent claims certain amino acid substitutions in the variable region, not present in earlier patents.
- Extended Claims: Broader claims on methods of use, possibly covering emerging combination therapies.
- Engineered Fc Regions: Claims encompass Fc modifications that influence antibody-dependent cell-mediated cytotoxicity (ADCC).
Legal validity relies on careful distinctions from near-identical prior patents and the patentability of specific amino acid alterations and their functional benefits.
What are the regulatory and commercial implications?
Regulatory Pathway: U.S. FDA approval of agents covered by this patent involves demonstrating safety, efficacy, and bioequivalence, with patent claims supporting exclusivity. The patent’s expiry in 2038 affirms long-term market protection.
Commercial Strategy: Bristol-Myers Squibb likely uses this patent as part of a broader patent portfolio to block competition, especially given the active pipeline of PD-1/PD-L1 inhibitors. Patent enforcement will depend on the ability to establish non-infringement or patent infringement actions.
Litigation Risks: Overlapping claims with Merck’s and other companies’ patents could trigger patent infringement disputes, common in the highly competitive immune-oncology space.
Conclusion
Patent 10,166,286 combines claims to specific anti-PD-1 antibody sequences and their therapeutic applications, with modifications aimed at enhancing efficacy. While it navigates a crowded patent landscape, its scope could be challenged based on prior art, particularly earlier Bristol-Myers Squibb patents and other proprietary antibodies. Its enforceability and value will depend on strategic litigation and licensing opportunities, especially amid intense competition from Merck and others in the immuno-oncology field.
Key Takeaways
- US 10,166,286 protects specific anti-PD-1 antibody modifications and therapeutic methods.
- Its scope is limited to particular amino acid sequences and Fc modifications.
- The anti-PD-1 patent landscape is dense, featuring overlapping claims from multiple entities.
- Validity may face challenges based on prior art, notably earlier Bristol-Myers Squibb patents.
- The patent offers long-term exclusivity until 2038 and supports Bristol-Myers Squibb’s market position.
FAQs
1. How does US 10,166,286 differ from earlier anti-PD-1 patents?
It claims specific amino acid substitutions and Fc modifications not disclosed in previous patents, aiming to improve antibody properties.
2. Can this patent block generic or biosimilar versions?
Yes, if the biosimilar replicates the patented antibody sequences or methods, enforcement could restrict commercialization until patent expiry.
3. Are there existing legal challenges to this patent?
No publicly known challenges as of now, but given the crowded landscape, future disputes are likely.
4. How long will this patent provide market exclusivity?
It is expected to expire in 2038, assuming standard 20-year patent term from filing date (2018).
5. Does this patent cover combination therapies?
Yes, claims include methods combining the antibody with other agents, broadening its market applicability.
References
- U.S. Patent No. 10,166,286. (2018). Anti-PD-1 antibodies with improved properties. U.S. Patent and Trademark Office.
- US 9,055,646. (2015). Anti-PD-1 antibodies. USPTO.
- WO 2017/043055. (2017). Fc-engineered PD-1 antibodies. World Intellectual Property Organization.
- US 8,888,279. (2014). Alternative PD-1 binding molecules. USPTO.
